Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 10, Pages 1553-1558Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.10.1553
Keywords
bispecific antibody; breast cancer; CD3; HER/2 neu; immunotherapy; trifunctional antibody
Categories
Ask authors/readers for more resources
Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with preferential binding to activating Fc gamma type I/III-receptors, resulting in the formation of a tri-cell complex among tumour cell, T cell and accessory cell. Recently, the antibody demonstrated antitumour efficacy against HER2/neu low-expressing tumours resistant to trastuzumab. Data from a completed Phase I study in metastatic breast cancer patients indicates strong immune responses. Owing to efficient tumour cell destruction by humoral and T-cell-dependent mechanisms, differing from conventional HER2/neu directed treatments, and a potential for long-lasting antitumour immunoreactivity, ertumaxomab is at present investigated within Phase 11 studies enrolling metastatic breast cancer patients even without HER2/neu gene amplification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available